859 related articles for article (PubMed ID: 19143029)
21. Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Lu X; Hsieh TC; Wu JM
Int J Oncol; 2004 Dec; 25(6):1801-7. PubMed ID: 15547720
[TBL] [Abstract][Full Text] [Related]
22. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
Gunawardena K; Campbell LD; Meikle AW
Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
[TBL] [Abstract][Full Text] [Related]
23. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
24. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
25. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
Chiang CF; Son EL; Wu GJ
Prostate; 2005 Sep; 64(4):408-18. PubMed ID: 15789364
[TBL] [Abstract][Full Text] [Related]
26. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
27. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
28. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.
Arencibia JM; Del Rio M; Bonnin A; Lopes R; Lemoine NR; López-Barahona M
Int J Oncol; 2005 Dec; 27(6):1617-23. PubMed ID: 16273218
[TBL] [Abstract][Full Text] [Related]
29. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
[TBL] [Abstract][Full Text] [Related]
30. Action mechanism and signal pathways of Psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells.
Chen KC; Peng CC; Chiu WT; Cheng YT; Huang GT; Hsieh CL; Peng RY
Nutr Cancer; 2010; 62(2):260-70. PubMed ID: 20099201
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
32. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
33. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
34. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
35. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
36. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
37. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.
Gao J; Isaacs JT
Cancer Res; 1998 Aug; 58(15):3299-306. PubMed ID: 9699659
[TBL] [Abstract][Full Text] [Related]
38. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
39. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
[TBL] [Abstract][Full Text] [Related]
40. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
